Constellation Pharmaceuticals To Present at First Annual Boston Biotech R&D Conference
CAMBRIDGE, MA – October 20, 2008 – Constellation Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs targeting selective regulators of epigenetic function, today will present at the 2008 Boston Biotech R&D Conference, at 3:40 PM, October 22, 2008 at Harvard Medical School in Boston, Mass.
Robert Tepper, M.D., Constellation Chief Scientific Officer and Third Rock Venture Partner, will provide an overview of the company, the Constellation product engine and the link between epigenetics and disease. The session will be moderated by Michael King of Rodman & Renshaw, LLC.
“We are pleased to be participating in the first Boston Biotech R & D conference, at which we will discuss the exciting science of epigenetics, and share insight into Constellation’s leadership and progress within the field,” said Robert Tepper, M.D., Constellation CSO and Third Rock Venture Partner.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene function and expression. Constellation’s primary focus is in oncology, but the company’s platform will also be applicable to other therapeutic areas including autoimmune, inflammatory and neurological diseases. The Company’s founders represent the core thought leaders in Epigenetics, responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at constpharma.wpengine.com.
About the Boston Biotech R&D Conference
The 2008 Boston Biotech R&D Conference will take place at Harvard Medical School and will highlight the work of top academics as well as up-and-coming biotech companies in the Boston area. The agenda features keynotes from several luminaries in medicine and research, including Jeffrey S. Flier, Dean of Harvard Medical School, Leonard Guarente, Ronald Kahn, Eric S. Lander, Robert Langer, Phillip Sharp, David Sinclair, as well as CEOs of the next generation of leading biotech and pharma companies from the Boston area. The conference is sponsored by Alexandria Real Estate Equities Inc., Pure Communications Inc. and Rodman & Renshaw, LLC. For more information, visit www.bostonbiotechconference.com.
Yates Public Relations